Regeneron Pharmaceuticals Inc $341.51

down -3.77


21/8/2014 04:00 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has outperformed the S&P 500 by 28%

Partner Headlines

  1. Qihoo, Regeneron Among 5 Stocks With Top Fundamentals

    IBD
  2. Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

    IBD
  3. Drugmaker Q2 Profits Robust

    IBD
  4. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  5. Deutsche Bank Raises Regeneron's Price Target To $425

    Benzinga
  6. UPDATE: Regeneron Posts Upbeat Q2 Results

    Benzinga
  7. Earnings Scheduled For August 5, 2014

    Benzinga
  8. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD
  9. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  10. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  11. Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples

    IBD
  12. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  13. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  14. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  15. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  16. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following ...

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  19. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  20. Pharmas Soar To New Highs

    IBD
  21. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  22. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  23. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  24. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  25. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  26. EYLEA Injection Recommended For Approval Regarding Treatment Of Visual ...

    Benzinga
  27. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  28. Major Indexes Narrowly Lower As Actavis Rallies

    IBD
  29. Regeneron Shares Fall Following BMO's Note Of Roche Preference

    Benzinga
  30. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  31. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  32. Valeant EPS Tops, Sales Miss

    IBD
  33. Valeant Reports Mixed Q1 Amid Drug Earnings Bonanza

    IBD
  34. Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

    IBD
  35. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  36. RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

    Benzinga
  37. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  38. Benzinga's Top Initiations

    Benzinga
  39. Top 40 Upcoming Earnings Releases

    Benzinga
  40. Biotechs Struggling To Find A Bottom

    Benzinga
  41. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  42. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  43. Cholesterol drug meets goal

    IBD
  44. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  45. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  46. Gilead Adds To Biotech Woes

    IBD
  47. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  48. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  49. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  50. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
Trading Center